Program
glepaglutide
Also written as “Glepaglutide”, “ZP1848” and “Glepaglutide 10 mg”.
Its studies are mostly in Short Bowel Syndrome · Renal Insufficiency · Inflammatory Bowel Diseases, led by Zealand Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zealand Pharma | 112 open or running | phase 3since Sep 17, 2018 | Mar 23, 2009 | Sep 18, 2028phase 3 · NCT07228403 |
Also a collaborator on its studies: larix-a-s.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 23, 2009First study: phase 1 study in Inflammatory Bowel DiseasesFirst studyNCT00868660 · 66 enrolled · United States
- Feb 12, 2016Phase 2 study in Short Bowel SyndromeNCT02690025 · 18 enrolled · Denmark
- Sep 5, 2017Phase 1 study in Healthy SubjectsNCT03279302 · 75 enrolled · United States
- Sep 17, 2018Phase 3 study in Short Bowel SyndromeNCT03690206 · 106 enrolled · United States, Belgium, Canada and more
- Mar 28, 2019Phase 3 study in Short Bowel SyndromeNCT03905707 · 150 enrolled · United States, Belgium, Canada and more
- Nov 25, 2019Phase 1 study in Renal InsufficiencyNCT04178447 · 16 enrolled · Hungary, Poland
- Mar 20, 2020Phase 1 study in HealthyNCT04318743 · 85 enrolled · Netherlands
- Apr 22, 2021Phase 3 study in Short Bowel SyndromeNCT04881825 · 84 enrolled · United States, Belgium, Denmark and more
- Jul 14, 2021Phase 3 study in Short Bowel SyndromeNCT04991311 · 12 enrolled · Denmark
- Sep 26, 2025Phase 3 study in Short Bowel SyndromeNCT07197944 · 90 planned · United States, Austria, Belgium and more
- Nov 13, 2025Phase 3 study in Short Bowel SyndromeNCT07228403 · 28 enrolled · United States, Belgium, Canada and more
Ahead
- Sep 18, 2028Primary completion: phase 3 study in Short Bowel SyndromeNCT07228403
- Oct 23, 2028Primary completion: phase 3 study in Short Bowel SyndromeNCT07197944
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07228403Short Bowel Syndrome · United States, Belgium, Canada and more | 3 | Active, not recruiting | Sep 18, 2028 | 28 |
| NCT07197944Short Bowel Syndrome · United States, Austria, Belgium and more | 3 | Recruiting | Oct 23, 2028 | 90 |
| NCT04991311Short Bowel Syndrome · Denmark | 3 | Completed | Feb 2, 2023 | 12 |
| NCT04881825Short Bowel Syndrome · United States, Belgium, Denmark and more | 3 | Completed | Apr 30, 2026 | 84 |
| NCT04318743Healthy · Netherlands | 1 | Completed | Jun 10, 2021 | 85 |
| NCT04178447Renal Insufficiency · Hungary, Poland | 1 | Completed | Jul 14, 2020 | 16 |
| NCT03905707Short Bowel Syndrome · United States, Belgium, Canada and more | 3 | Completed | Apr 30, 2026 | 150 |
| NCT03690206Short Bowel Syndrome · United States, Belgium, Canada and more | 3 | Completed | Jul 26, 2022 | 106 |
| NCT03279302Healthy Subjects · United States | 1 | Completed | Dec 18, 2017 | 75 |
| NCT02690025Short Bowel Syndrome · Denmark | 2 | Completed | May 2017 | 18 |
| NCT00868660Inflammatory Bowel Diseases · United States | 1 | Completed | Feb 2010 | 66 |
How it is read
Names in the registry
- “Glepaglutide”, 6 entries
- “glepaglutide”, 2 entries
- “ZP1848”, 2 entries
- “Glepaglutide 10 mg”, 1 entry
Conditions, from the studies’ own filings
- Short Bowel Syndrome, 7 studies
- Renal Insufficiency, 1 study
- Inflammatory Bowel Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.